Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascentage Pharma Group InternationalAAPG -8.14%57 Cyclically Adjusted PB Ratio is 24.39 as of Jul. 17, 2026, which is 18% below its 10-year median of 29.76. GuruFocus rates AAPG with a GF Score™ of 57/100 and a GF Value™ of $26.23 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 697 Biotechnology companies, Ascentage Pharma Group International ranks worse than 95.7% on this metric.
The historical rank and industry rank for Ascentage Pharma Group International's Cyclically Adjusted PB Ratio or its related term are showing as below:
AAPG'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 19.92 Med: 29.76 Max: 35.92
Current: 23.43
During the past 10 years, Ascentage Pharma Group International's highest Cyclically Adjusted PB Ratio was 35.92. The lowest was 19.92. And the median was 29.76.
AAPG's Cyclically Adjusted PB Ratio is ranked worse than 95.7% of 697
companies
in the Biotechnology industry
Industry Median: 1.63
vs AAPG: 23.43
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Ascentage Pharma Group International's adjusted book value per share data of for the fiscal year that ended in Dec25 was $2.015. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.76 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Ascentage Pharma Group International (NAS:AAPG) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Ascentage Pharma Group International Cyclically Adjusted PB Ratio Related Terms
Ascentage Pharma Group International Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Cyclically Adjusted PB Ratio Chart
AAPG vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Cyclically Adjusted PB Ratio falls into.
Ascentage Pharma Group International Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 24.39 mean?
Ascentage Pharma Group International (AAPG) has a Cyclically Adjusted PB Ratio of 24.39 as of Jul. 17, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascentage Pharma Group International and its competitors. This is 18% below median its historical median of 29.76. Over the past decade, Ascentage Pharma Group International's Cyclically Adjusted PB Ratio has ranged from 19.92 to 35.92. According to the industry distribution chart, Ascentage Pharma Group International ranks #667 out of 697 companies in the Biotechnology industry, placing it in the top 95.7%.
Is Ascentage Pharma Group International's Cyclically Adjusted PB Ratio too high?
Ascentage Pharma Group International's current Cyclically Adjusted PB Ratio of 24.39 is 18% below median its 10-year median of 29.76. Over the past 10 years, this metric has ranged from a low of 19.92 to a high of 35.92. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.63. Ascentage Pharma Group International's value of 24.39 is 1396.3% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #667 out of 697 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #667 out of 697 companies for Cyclically Adjusted PB Ratio. This places Ascentage Pharma Group International in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.63. Ascentage Pharma Group International's value of 24.39 is 1396.3% above this benchmark. Historically, Ascentage Pharma Group International's own Cyclically Adjusted PB Ratio has ranged from 19.92 to 35.92 over the past decade. While the company's 10-year median is 29.76 vs. the industry median of 1.63, Ascentage Pharma Group International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.63, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Cyclically Adjusted PB Ratio of 24.39 is 1396.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Cyclically Adjusted PB Ratio is 24.39, which is 18% below median its own 10-year median of 29.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (AAPG) is currently considered Modestly Undervalued. The stock's GF Value™ is $26.23, compared to a current price of $18.54 — trading 29.3% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 24.39, which is 18% below median its 10-year median of 29.76 and 1396.3% above the Biotechnology industry median of 1.63. Ascentage Pharma Group International's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Ascentage Pharma Group International (AAPG), the current Cyclically Adjusted PB Ratio is 24.39 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (AAPG) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $18.54 is trading 29.3% below its estimated GF Value™ of $26.23.
GuruFocus considers Ascentage Pharma Group International to be Modestly Undervalued.
Key valuation signals for AAPG:
Cyclically Adjusted PB Ratio: 24.39 (18% below median its 10-year median of 29.76)
GF Value™: $26.23 vs. price of $18.54 (29.3% below fair value)
Industry Position: 1396.3% above the Biotechnology median (#667 of 697)
No single metric tells the full story. See the AAPG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
57GF Score
Get the complete analysis for AAPG
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AAPG has been successfully added to your 
